Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Dasatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 13 Jun 2019 Status changed from active, no longer recruiting to completed.
- 18 Mar 2019 Results published in the British Journal of Cancer
- 09 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.